Cargando…
Human dimethylarginine dimethylaminohydrolase 1 inhibition by proton pump inhibitors and the cardiovascular risk marker asymmetric dimethylarginine: in vitro and in vivo significance
Proton pump inhibitor (PPI)-induced inhibition of dimethylarginine dimethylaminohydrolase 1 (DDAH1), with consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA), might explain the increased cardiovascular risk with PPI use. However, uncertainty exists regar...
Autores principales: | Tommasi, S., Elliot, D. J., Hulin, J. A., Lewis, B. C., McEvoy, M., Mangoni, A. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460274/ https://www.ncbi.nlm.nih.gov/pubmed/28588208 http://dx.doi.org/10.1038/s41598-017-03069-1 |
Ejemplares similares
-
A multicentric consortium study demonstrates that dimethylarginine dimethylaminohydrolase 2 is not a dimethylarginine dimethylaminohydrolase
por: Ragavan, Vinitha N., et al.
Publicado: (2023) -
Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development
por: Murphy, Rhys B., et al.
Publicado: (2016) -
MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1
por: Hulin, Julie-Ann, et al.
Publicado: (2017) -
Inhibition of Dimethylarginine Dimethylaminohydrolase (DDAH) Enzymes as an Emerging Therapeutic Strategy to Target Angiogenesis and Vasculogenic Mimicry in Cancer
por: Hulin, Julie-Ann, et al.
Publicado: (2020) -
Mechanical force promotes dimethylarginine dimethylaminohydrolase 1-mediated hydrolysis of the metabolite asymmetric dimethylarginine to enhance bone formation
por: Xie, Ziang, et al.
Publicado: (2022)